Loading organizations...
§ Private Profile · Atlanta, GA, USA
Biopharmaceutical company developing neutrophil-modulating treatments for inflammatory diseases like cystic fibrosis and severe acne.
Founded in 2007 by William Reddick, Celtaxsys is an Atlanta, Georgia-based biopharmaceutical company developing specialized treatments that modulate neutrophils within the immune system to address various rare inflammatory diseases. The privately held enterprise focuses its clinical pipeline on advancing targeted therapies for complex medical conditions, specifically prioritizing cystic fibrosis and severe acne. Backed by institutional investors including GRA Ventures, the biotechnology firm has successfully raised $32.9 million in total venture funding to support its ongoing drug development programs. The company currently operates with a dedicated team of 10 to 50 employees and generates between $5 million and $25 million in estimated annual revenue. Executive leadership has included notable industry figures such as former chief executive officers Michael Hanley and Greg Duncan, overseeing a highly stable workforce where 69% of personnel have tenures exceeding eleven years.
Celtaxsys has raised $45.0M across 1 funding round.
Celtaxsys has raised $45.0M in total across 1 funding round.
Celtaxsys has raised $45.0M across 1 funding round. Most recently, it raised $45.0M Grant / Series D in June 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 8, 2015 | $45M Grant | Nicole Vitullo | Cystic Fibrosis Foundation, Georgia Research Alliance, Gerry Brunk, Masters Capital Management, Maxim Gorbachev | Announced |
Celtaxsys has raised $45.0M in total across 1 funding round.
Celtaxsys's investors include Nicole Vitullo, Cystic Fibrosis Foundation, Georgia Research Alliance, Gerry Brunk, Masters Capital Management, Maxim Gorbachev.